Hs.137007 is a novel epigenetic marker hypermethylated and up-regulated in breast cancer
By: Kim TW, Kim YJ, Lee HJ, Min SY, Kang HS, Kim SJ.

Department of Life Science, Dongguk Univ-Seoul, Seoul 100-715, Korea.
Int J Oncol. 2010 May; 36(5):1105-11.

Abstract

This study was conducted to mine novel breast-specific unigenes and analyze their epigenetic regulation in breast cancer. Differential digital display and methylation analysis identified the Hs.137007 gene containing a Kelch domain as a candidate novel epigenetic marker. In 50 pairs of breast cancer tissues and nearby normal tissues the methylation level of the 14 CpG sites at the promoter region (-778 to -485) of the gene was higher in cancer tissues (72-93%) than in normal tissues (31-83%), with a high correlation rate (p<0.05). End-point RT-PCR and real-time RT-PCR revealed that Hs.137007 was up-regulated in cancer tissues. A clear relationship between high methylation levels and up-regulated expression was also observed in the cultured breast cell lines. The MCF7 (90-100%) and MDAMB468 (100%) cancer cell lines that showed higher methylation than the BT549 (20-90%) and 184B5 (10-100%) at the 14 CpGs also showed elevated gene expression. Taken together, these results indicate that the Hs.137007 gene is a novel gene specifically expressed in the breast that can be utilized as an epigenetic marker of breast cancer.

PMID: 20372783 [PubMed - in process] Source: National Library of Medicine.






* Albert Einstein College of Medicine has been
awarded Acceditation with Commendation by
the ACCME

Copyright 2025 InterMDnet | Privacy Policy | Disclaimer | System Requirements